BioCentury | Apr 20, 2018
Clinical News

Celldex discontinues development of glembatumumab vedotin after TNBC failure

...next most advanced candidates are varlilumab (CDX-1127), which is a human mAb targeting CD27, and CDX-3379...
...company plans to complete enrollment of the first stage of a Phase II trial evaluating CDX-3379...
BioCentury | Apr 16, 2018
Clinical News

Celldex routed after TNBC failure

...next most advanced candidates are varlilumab (CDX-1127), which is a human mAb targeting CD27, and CDX-3379...
...company plans to complete enrollment of the first stage of a Phase II trial evaluating CDX-3379...
BioCentury | Nov 4, 2016
Company News

Kolltan, Celldex deal

...a humanized IgG1 mAb targeting stem cell factor (SCF) receptor tyrosine kinase (c-Kit; KIT; CD117). KTN3379...
...Kolltan Pharmaceuticals Inc. , New Haven, Conn. Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Business: Cancer Chris Lieu KTN0158 KTN3379 Celldex...
BioCentury | Nov 1, 2016
Company News

Celldex acquiring Kolltan

...tyrosine kinases. KTN0158 is in a dose escalation study in refractory gastrointestinal stromal tumors (GIST). KTN3379...
BioCentury | Jun 13, 2016
Clinical News

KTN3379: Updated Phase I data

...advanced solid tumors in the 2-part, open-label, U.S. Phase I KTN3379-CL-001 trial showed that IV KTN3379...
...response in a patient with squamous cell carcinoma of the head and neck (SCCHN). Additionally, KTN3379...
...plus a case of stable disease in a patient with colorectal cancer. Patients received IV KTN3379...
BioCentury | Nov 9, 2015
Clinical News

KTN3379: Phase Ib started

...Kolltan began an open-label, U.S. Phase Ib trial to evaluate 1,000 mg IV KTN3379 every 2...
...then receive KTN3379 plus Zelboraf and 131I. Kolltan Pharmaceuticals Inc. , New Haven, Conn. Product: KTN3379...
...ORR) and proportion of patients alive without disease progression at 6 months following treatment with KTN3379...
BioCentury | Nov 9, 2015
Clinical News

KTN3379: Phase I started

...Kolltan began an open-label, U.S. Phase I trial to evaluate KTN3379 prior to surgical resection of...
...29 HPV-negative and HPV-positive patients with SCCHN. Kolltan Pharmaceuticals Inc. , New Haven, Conn. Product: KTN3379...
BioCentury | Jun 29, 2015
Clinical News

KTN3379: Interim Phase I data

...patients with advanced solid tumors in a 2-part, open-label, U.S. Phase Ib trial showed that KTN3379...
...received 20 mg/kg IV KTN3379 every 3 weeks plus Erbitux, Tarceva erlotinib, Zelboraf or Herceptin. KTN3379...
...fatigue reported as the most common treatment-emergent adverse events. The recommended Phase II dose of KTN3379...
BioCentury | Jan 29, 2015
Financial News

Kolltan withdraws IPO

...Kolltan said it expected to report data this half from its Phase Ib trial of KTN3379...
BioCentury | Sep 13, 2014
Financial News

Cancer play Kolltan files for IPO

...IPO on NASDAQ underwritten by Leerink Partners; Stifel; Guggenheim Securities; and Janney Montgomery Scott. Kolltan's KTN3379...
Items per page:
1 - 10 of 13